These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33560216)

  • 61. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.
    Kalter JA; Yang RA; Toland A; Milla S; Lund TC; Hankinson T; Dahl NA
    J Neuropathol Exp Neurol; 2024 Mar; 83(4):289-292. PubMed ID: 38456320
    [No Abstract]   [Full Text] [Related]  

  • 63. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
    Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
    Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features.
    Nasrallah MLP; Desai A; O'Rourke DM; Surrey LF; Stein JM
    Acta Neuropathol Commun; 2020 Jul; 8(1):115. PubMed ID: 32690110
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas.
    Feller C; Felix M; Weiss T; Herold-Mende C; Zhang F; Kockmann T; Sahm F; Aebersold R; von Deimling A; Reuss DE
    Acta Neuropathol; 2020 Jan; 139(1):211-213. PubMed ID: 31773240
    [No Abstract]   [Full Text] [Related]  

  • 68. Diagnosis and treatment for pure aqueductal tumor.
    Tamura R; Miwa T; Ohira T; Yoshida K
    J Clin Neurosci; 2017 Oct; 44():260-263. PubMed ID: 28690017
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas.
    Venneti S; Felicella MM; Coyne T; Phillips JJ; Gorovets D; Huse JT; Kofler J; Lu C; Tihan T; Sullivan LM; Santi M; Judkins AR; Perry A; Thompson CB
    J Neuropathol Exp Neurol; 2013 Apr; 72(4):298-306. PubMed ID: 23481705
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
    Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Histologic Low-Grade Glioma with 7 Gain, 10 Loss-A Wolf in Sheep's Clothing.
    Pollom EL; Soltys SG
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1137-1138. PubMed ID: 33714521
    [No Abstract]   [Full Text] [Related]  

  • 79. Recurrent high-grade astrocytoma with somatic mosaicism of isocitrate dehydrogenase gene mutation.
    Masui K; Onizuka H; Nitta M; Muragaki Y; Kawamata T; Komori T
    Pathol Int; 2023 Mar; 73(3):144-146. PubMed ID: 36645206
    [No Abstract]   [Full Text] [Related]  

  • 80. Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.
    Takahashi K; Usuzaki T; Inamori R
    Korean J Radiol; 2023 Dec; 24(12):1303-1305. PubMed ID: 38016690
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.